Aspira Women's Health Q3 rev $2.3M, cash burn $2.9M, reaffirms FY 2024 cash guidance

Aspira Women's Health Inc.

2024-Q3 EPS reported -$0.88 vs consensus -$0.25 ▼ miss (-255.6%)

Q3 OvaSuite revenue $2.3M (+2% YoY); test volume 6,001 units (+4% YoY).
OvaWatch volume grew 27% YoY, now 22% of total test volume.
Cash used in ops $2.9M, down 12% from Q2; FY 2024 cash burn guidance reaffirmed $13.0-14.5M.
Awarded $10M ARPA-H contract for ENDOinform; expects first $2M payment by year-end.
Gross margin 60% (vs 59% YoY); sales & marketing up 26% but G&A down 25%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.